top of page

Industry-sponsored Research

List of completed and ongoing studies

  1. A Global ATHerombosis Assess (AGATHA) Study (international multicentre) in Malaysia. 

  2. A Multi-centre, double blind, randomized, parallel group study to evaluate the effects of two different doses of Losartan on morbidity & mortality in patients with symptomatic heart failure intolerant to ACEi (HEAAL)

  3. Epidemiology Study of the Correlation Between the Measurement of the Intima-Media Thickness of the Wall of the Common carotid Artery and the Calculation of the Absolute Cardiovascular Risk (IMT-PARC)

  4. A multicentre, randomized, double blind, placebo-controlled "Factrial" design study to evaluate the lipid-altering efficacy & safety of Ezetimbe/Simvastatin Combination tablet in patient with primary hypercholesterolaemia.

  5. A Randomised Study With The Sirolimus-Eluting Bx Velocity Balloon Expandable Stent In The Treatment of Diabetic Patients With Native Cpronary Artery Lesions (DECODE)

  6. Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE)

  7. Post Market Survey of TSUnami CoRonary Stent System In Europe & Asia (MATSURI)

  8. Asia Pacific Acute Myocardial Infarct Trial (APAMIT)

  9. DirEct versus Conventional Stenting In Diabetics Undergoing Elective Angioplasty trial (DECIDE)

  10. International randomised study evaluating the efficacy & safety of fondaparinux sodium vs control therapy and glucose-insulin-potassium infusion versus control in a broad range of patients with ST segment elevation acute myocardial infarction (MICHELANGELO : OASIS 6)

  11. Enoxaparin and thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis In Myocardial Infarction – Study 25 (ExTRACT – TIMI 25)

  12. An international prospective observational registry in subjects at risk of atherothrombotic events (REACH)

  13. Clinical utility of Amlodipine/Atorvastatin to improve  concomitant cardiovascular risk factors of hypertension and dyslipidemia (GEMINA-AALA)

  14. Registry on Intravenous Anticoagulation in the Real  world of Angioplasty (RIVIERA)

  15. Acute Coronary Syndromes Descriptive Study (ACCORD)

  16. An open-label, randomized, multi-centre, phase IIIb/IV, parallel group study to compare the efficacy and safety of rosuvastatin and atorvastatin in subjects with type IIa and Iib hypercholesterolaemia (DISCOVERY)

  17. TAXUS OLYMPIC Registry – A Global TAXUS Liberte Drug Eluting Stent System Registry Program

  18. Genous Bio-engineered R Stent Post Marketing Registry (e-HEALING)

  19. Phase III, Multicentre, Open-Label, Dose Titrating, 16-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoximil 20mg and 40mg Alone or in combination with 12.5mg to 25mg of hydrochlorothizidine subjects with mild to moderate essential hypertension (OSCAR)

  20. Biolimus-Eluting A-9 Coronary Stent Obviating Luminal Narrowing Internet Based Registry (BEACON)

  21. A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.d. for the prevention of cardiovascular Hospitalization or death from any cause in patients with Atrial fibrillation/atrial flutter (ATHENA)

  22. Randomized, doubleblind, parallel- group, multicenter study to evaluate the safety and efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg compared to amlodipine 5 mg and 10 mg in hypertensive patients not adequately responsive to amlodipine 5 mg (CSPP100A23305)

  23. Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome:  A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (Early-ACS)

  24. A phase IIIb-IV, randomized, open label trial evaluating the efficacy and safety of tenecteplase together  with unfractionated heparin prior to early PCI as compared to standard primary PCI in patients with acute myocardial infarction. (ASSENT IV)

  25. Randomized Evaluation of Long term anticoagulant therapy (RELY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RELY Study)

  26. MK-524B/Protocol No. 022. A multicenter, randomized, double-blind, “Factorial” design study to evaluate the lipid altering efficacy and safety of MK-0524b combination tablet in patients with primary hypercholesterolemia or mixed hyperlipidemia

  27. A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in patients with non-ST elevation acute coronary syndrome and planned early invasive strategy (SEPIA ACS)

  28. A prospective randomized study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in patients with uncontrolled hypertension who fail to respond adequately to treatment with a fixed dose of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg

  29. Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)

  30. Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO)

  31. Systolic Heart Failure treatment with the If inhibitor ivabradine Trial (SHIFT)

  32. INternational Study of Prediction of Intra-abdominal adiposity and its RElationships with cardioMEtabolic risk / Intra-Abdominal Adiposity (INSPIRE ME / IAA)

  33. Awareness of Abdominal Adiposity As A marker of cardiometabolic risk (5A Registry)

  34. Clopidogrel optimal loading dose Usage to Reduce Recurrent EveNTs (CURRENT) Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or non-ST segment elevation myocardial infarction managed with an early invasive strategy (CURRENT)

  35. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

  36. A Study of PLATelet inhibition and Patinet Outcomes (PLATO)

  37. International PRospective Multicenter Study On RadiaTion Dose Estimates Of Coronary CT AngIOgraphy IN Daily Practice (PROTECTION)

  38. Patient Related OuTcome with Endeavor vs Cypher stenting Trial (PROTECT)

  39. A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK-0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia (CROSSOVER)

  40. Paclitaxel-Eluting Balloon Angioplasty and Cobalt Chromium Stents versus Conventional Angioplasty and paclitaxel Eluting Stents in the treatment of native Coronary artery Stenoses of Diabetic patients. (PEPCAD)

  41. A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation. (ROCKET AF)

  42. COronary artery Myocardial Perfusion Late Enhancement magneTic resonance Evaluation. (COMPLETE)

  43. A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous  biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation (BOREALIS-AF) Study

  44. Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial (AVERROES)

  45. A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Hypercholesterolemia or Mixed Hyperlipidemia (DEFINE Study)

  46. Multicentre, rAndomized, parallel Group Efficacy superiority study in hospitalized medically iLL patients comparing rivaroxabAN (MAGELLAN) study

  47. A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subject with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist for Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2ºP-TIMI 50)

  48. An open label, non comparative, observational study to evaluate the efficacy, safety, and tolerability of Co-Diovan® (Valsartan+HCTZ) in Asian patients with essential hypertension

  49. The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome (ATLAS ACS 2 TIMI 51)

  50. A multicenter study comparing the efficacy and safety of biotinylated idraparinux (SSR126517E) with warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation

  51. Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease trial (BEST)

  52. A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of Up to Two De Novo Coronary Artery Lesions (PLATINUM) 

  53. Paclitaxel-Eluting BallOon and Bioengineered ProgeniTor Cell-Attracting StainlEss Steel SteNT in the Treatment of Coronary Artery Stenosis: A Post-Marketing Surveillance Registry (POTENT)

  54. A Multi-center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA·CER)

  55. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid -Modifying Effect and Tolerability of MK1903 in Patients with Dyslipidemia

  56. Effects Of Ivabradine In Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-Blind Placebo-Controlled International Multicentre Study (SIGNIFY)

  57. A Randomized, Multicentre, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogeniticty, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery

  58. Regional CIMT Study 'Prevalence of Atherosclerotic Disease in Asian subjects not on lipid-lowering agents, but with at least two CVD risk factors

  59. Registry on Cardiac Rhythm Disorders : An International, Observational Prospectieb Survey Assessing The Control of Atrial Fibrillation in Asia Pacific (Record AF-AP)

  60. A comparison of Prasugrel and clopidogrel in with Acute Coronary Syndrome (ACS) with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) who are Medically Managed (TRILOGY)

  61. A Prospective, Randomized Study to Evaluate the Safety and Effectiveness of an Abluminal Sirolimus CoatED Bio-Engineered StEnt (Combo Bio-Engineered Sirolimus Eluting Stent) Compared with a TAXUS Liberte Stent Control Arm for Treatment of Stenotic Lesions in Native Coronary Arteries (REMEDEE)

  62. Prospective Observational Longitudinal Registry of Patients with Stable Coronary Artery Disease (CLARIFY)

  63. Randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy (TAO)

  64. Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population with Long Lesion(s) and/or Dual Vessels in Asia (RESOLUTE ASIA)

  65. Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with A Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D) (ALECARDIO Study)

  66. A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors (PALLAS)

  67. Long-tErm follow-uP of antithrombotIc management patterns In Acute CORonary Syndrome patients in Asia (EPICOR ASIA)

  68. EXenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus (EXSCEL)

  69. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

  70. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction (PARADIGM)

  71. A long term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (SUSTAIN 6) - National principal investigator 

  72. Global SYMPLICITY Registry (GSR) - Prospective, multi-center, non-interventional, single-arm, open-label registry of the Medtronic Symplicity Renal Denervation System that will document the long-term safety and effectiveness of renal denervation in a real world patient population with hypertension and/or other diseases characterized by elevated sympathetic drive - Principal investigator

  73. Xarelto® on prevention of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation in Asia: A non-interventional study (XANAP) - National principal investigator 

  74. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (ODYSSEY)

  75. Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) Prospective Observational Registry

  76. A Phase 3B Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with Stable Cardiovascular Disease and Glucose Abnormalities (AlePrevent)

  77. Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systolic dysfunction. A 6 to 12-month randomised double blind parallel groups multicentre study

  78. QUAlity of adherence to guideline recommendations for LIfe-saving treatment in heart failure: an international survey. (QUALIFY)

  79. Effects of ivabradine on plaque burden, morphology and composition in patients with clinically indicated coronary angiography. A randomised double-blind placebo-controlled international multicentre study (MODIFY)

  80. Multinational Abluminal Sirolimus Coated Bio-Engineered Stent Registry (MASCOT)

  81. A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events (DEVOTE)

  82. A multicenter, randomized, double-blind, placebo controlled phase III study to evaluate the efficacy, safety and tolerability of serelaxin when added to standard therapy in acute heart failure patients. (Relax Asia)

  83. A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER)

  84. A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes (PIONEER-6)

  85. Treatment of coronary in-stent restenosis by a sirolimus (rapamycin) coated balloon or a paclitaxel coated balloon-FIM-LIMUS-DCB

  86. A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of Stent Firehawk TM DES in the Treatment of Patients With Coronary Artery Lesions. The study will be considered complete (with regard to the primary endpoint) after all subjects have completed the 12-month follow-up. (TARGET)

  87. A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

  88. Prospective Observational study of Lipid Management in Non-US, Non-Western European Patients Who Have A Recent Acute Coronary Syndrome Event (ACOSYM)

bottom of page